Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: Effects on the endometrium

International Journal of Fertility and Women's Medicine

Volumn 42, Issue SUPPL. 2, 1997, Pages 388-398

  Johannisson, Elisabeth ^a,d   Holinka, Christian F ^b   Arrenbrecht, Stefan ^c  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b PharmConsult   (United States)

^c RW Johnson Pharmaceutical Res I   (Switzerland)

^d CYTOSEM   (Switzerland)

Author keywords

Endometrial hyperplasia; Endometrium; Estradiol; Histology; Hormone replacement therapy; Menopause; Norethisterone acetate; Transdermal

Indexed keywords

ESTRADIOL; EVOPAD; NORETHISTERONE ACETATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SAFETY; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLICULAR PHASE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADULT; BIOPSY; COHORT STUDIES; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE;

EID: 0031430993     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Carr BR, Wilson JD: Disorders of the ovary and female reproductive tract, in Isselbacher KJ, Braunwald E, Wilson JD, et al (eds): Harrison's Principles of Internal Medicine, 13th ed. New York, McGraw- Hill, pp 2017-2036, 1994.
2. Giudice LC, Ferenczy A: The endometrial cycle, in Adashi EY, Rock JA, Rosenwaks Z (eds): Reproductive Endocrinology, Surgery and Technology, vol 1. Philadelphia, Lippincott-Raven, pp 272-300, 1996.
3. Hargrove JT, Eisenberg E: Menopause. Med Clin North Am 79:1337-1356, 1995.
4. Sagraves R: Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. J Clin Pharmacol 35:2S-10S, 1995.
5. Thorneycroft IH: Practical aspects of hormone replacement therapy. Prog Cardiovasc Dis 38:243-255, 1995.
6. Zichella L: Clinical management of the menopausal woman. Int J Fertil 38(Suppl 1):15-22, 1993.
7. Gredmark T, Kvint S, Havel G, et al: Histopathological findings in women with postmenopausal bleeding. Br J Obstet Gynaecol 102:133-136, 1995.
8. Rose PG: Endometrial carcinoma. N Engl J Med 335:640-649, 1996.
9. Samsioe G: The endometrium: effects of estrogen and estrogen-progestogen replacement therapy. Int J Fertil 39(Suppl 2):84-92, 1994.
10. Woodruff JD, Pickar JH: Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 170:1213-1223, 1994.
11. Lobo RA: The role of progestins in hormone replacement therapy. Am J Obstet Gynecol 166:1997-2004, 1992.
12. Taitel HF, Kafrissen ME: Norethindrone - a review of therapeutic applications. Int J Fertil 40:207-223, 1995.
13. Whitehead MI, Hillard TC, Crook D: The role and use of progestogens. Obstet Gynecol 75(Suppl 4):59S-76S, 1990.
14. Johannisson E, Landgren BM, Rohr HP, Diczfalusy E: Endometrial morphology and peripheral hormone levels in women with regular menstrual cycles. Fertil Steril 38:564-571, 1987.
15. Rozenberg S, Ylikorkala O: Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. Int J Fertil 42(Suppl 2), 1997.
16. Udoff L, Langenberg P, Adashi EY: Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 86:306-316, 1995.
17. Korhonen MO, Symons JP, Hyde BM, et al: Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 176:377-380, 1997.
18. Sturdee DW, Barlow DH, Ulrich LG, et al: Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy? Lancet 343:979-982, 1994.
19. Notelovitz M, Varner RE, Rebar RW, et al: Minimal endometrial proliferation over a two-year period in postmenopausal women taking 0.3 mg of unopposed esterified estrogens. Menopause 4:80-88, 1997.
20. Granberg S, Ylöstalo P, Wikland M, et al: Endometrial sonographic and histologic findings in women with and without hormonal replacement therapy suffering from postmenopausal bleeding. Maturitas 27:35-40, 1997.
21. Kurman R: Blaustein's pathology of the female genital tract, New York, pp 466-471, 1994.